Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism

Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism: AYKAN Trial

The aim of the present study was to assess the effects of low-dose (25mg) prolonged administration (in 6 hours) of tissue type plasminogen activator (tPA) on in-hospital mortality and outcomes in patients with massive PE.

Study Overview

• Status: Unknown
• Conditions: Pulmonary Embolism
• Intervention / Treatment: Drug: 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours

Detailed Description

Pulmonary embolism (PE) is life threatening disease requiring early diagnosis and treatment. Thrombolytic therapy (TT) is required in patients with massive PE. PE has a high mortality but the in-hospital all-cause case mortality rates were lower in unstable patients who received TT than those who did not. However, it was reported that minority (nearly 30%) of unstable patients received thrombolytic therapy. The reason that majority of unstable patients failed to receive thrombolytic therapy is unclear. The higher rates of complications including the life threatening bleeding may be a reason of reluctance in the use of TT.

The lungs are the only organ receiving the entire cardiac output. Therefore, they are the point of convergence for the entire molecules of the thrombolytic agent, independent from the route of administration. So that lower doses of the TT might be effective in PE, with the additional benefits of enhancing its safety profile. The percutaneous endovenous intervention for deep venous thrombosis has suggested an exquisitely favorable pulmonary response to low-dose thrombolysis. The aim of the present study was to assess the effects of low-dose (25mg) prolonged administration (in 6 hours) of tissue type plasminogen activator (tPA) on in-hospital mortality and outcomes in patients with massive PE.

The primary end points consisted of in hospital all cause mortality, major complications, pulmonary hypertension and right ventricular dysfunction. Secondary points are all cause mortality, pulmonary hypertension and right ventricular dysfunction at 6 month.

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Phase 4

Contacts and Locations

Study Locations

• Turkey
  • Trabzon, Turkey, 61040
    • Recruiting
    • Department of Cardiology, Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital
    • Principal Investigator: AHMET Ç AYKAN, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Patients with massive PE aged 18 years or older with confirmed PE and able to give informed consent will be included in the study. PE is defined according to current guidelines as adult patients presenting with signs and symptoms suggestive of PE plus imaging documentation on computed tomography angiography. Massive PE was defined as acute PE with sustained hypotension (systolic blood pressure<90 mm Hg for at least 15 minutes or requiring inotropic support, not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or left ventricular [LV] dysfunction), pulselessness, or persistent profound bradycardia (heart rate<40 bpm with signs or symptoms of shock).

Exclusion Criteria:

Patients with prior intracranial hemorrhage, known structural intracranial cerebrovascular disease (eg, arteriovenous malformation), known malignant intracranial neoplasm, ischemic stroke within 3 months, suspected aortic dissection, active bleeding or bleeding diathesis, recent surgery encroaching on the spinal canal or brain, and recent significant closed-head or facial trauma with radiographic evidence of bony fracture or brain injury were excluded from the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Low dose prolonged infusion arm; Low dose prolonged infusion of tPA arm (25mg Actilyse in 6 hours)	Drug: 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
All cause in hospital mortality	Death occured during hospitalization period.	participants will be followed for the duration of hospital stay, an expected average of 7 days
Major complications	Major bleeding, intracranial bleeding, resuscitated cardiac arrest, thromboembolism and stroke are described as major complications.	participants will be followed for the duration of hospital stay, an expected average of 7 days.
Development of pulmonary hypertension	Pulmonary artery systolic pressure >40mmHg measured by transthoracic echocardiography prior to discharge was described as pulmonary hypertension.	participants will be followed for the duration of hospital stay, an expected average of 7 days
Right Ventricular dysfunction	Right ventricular dysfunction detected by transthoracic echocardiography: Decreased right ventricular diameter (at least 25% decrease of Right ventricle/Left ventricle diameter); Tricuspid annular plane systolic excursion>16mm); s'> 10.0 cm/s; Tissue Doppler derived right ventricle myocardial performance index>0.55	participants will be followed for the duration of hospital stay, an expected average of 7 days
Restoration of hemodynamic status	Systolic blood pressure >100mmHG	6 hours after the beginning of thrombolytic therapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pulmonary hypertension	Pulmonary artery systolic pressure >40mmHg	6 month
Right ventricular dysfunction	Tricuspid annular plane systolic excursion >16mm; s'> 10.0 cm/s; Tissue Doppler derived right ventricle myocardial performance index>0.55; Right ventricle/Left ventricle diameter <1	6 months

Collaborators and Investigators

• Sponsor: Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital
• Investigators: Study Chair: Ahmet Ç AYKAN, MD, Department of Cardiology, Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital

Publications and helpful links

General Publications

• Ozkan M, Cakal B, Karakoyun S, Gursoy OM, Cevik C, Kalcik M, Oguz AE, Gunduz S, Astarcioglu MA, Aykan AC, Bayram Z, Biteker M, Kaynak E, Kahveci G, Duran NE, Yildiz M. Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator. Circulation. 2013 Jul 30;128(5):532-40. doi: 10.1161/CIRCULATIONAHA.113.001145. Epub 2013 Jun 28.
• Ozkan M, Gunduz S, Biteker M, Astarcioglu MA, Cevik C, Kaynak E, Yildiz M, Oguz E, Aykan AC, Erturk E, Karavelioglu Y, Gokdeniz T, Kaya H, Gursoy OM, Cakal B, Karakoyun S, Duran N, Ozdemir N. Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. JACC Cardiovasc Imaging. 2013 Feb;6(2):206-16. doi: 10.1016/j.jcmg.2012.10.016.

Study record dates

Study Major Dates

• Study Start: June 1, 2011
• Primary Completion (Anticipated): March 1, 2014
• Study Completion (Anticipated): August 1, 2014

Study Registration Dates

• First Submitted: November 17, 2013
• First Submitted That Met QC Criteria: January 7, 2014
• First Posted (Estimate): January 8, 2014

Study Record Updates

• Last Update Posted (Estimate): January 8, 2014
• Last Update Submitted That Met QC Criteria: January 7, 2014
• Last Verified: January 1, 2014

More Information

Terms related to this study

• Keywords: elderly; high risk; thrombolytic therapy; Massive Pulmonary embolism
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Lung Diseases; Embolism and Thrombosis; Embolism; Pulmonary Embolism; Molecular Mechanisms of Pharmacological Action; Fibrinolytic Agents; Fibrin Modulating Agents; Tissue Plasminogen Activator
• Other Study ID Numbers: 538.38792-903/6190